Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2013

View Archived Issues

Results reported for volasertib plus low-dose cytarabine therapy in AML patients

Alize Pharma launches collaborative research program for AZP-531

Chroma receives milestone payment from GSK for HDAC inhibitor

Tumor-suppressing MAb demonstrates preclinical antitumor efficacy

BRD-9876 identified as potential therapeutic candidate in niche-based screening

Novel guanylate cyclase activators disclosed by Astellas Pharma

U.S. researchers present new protein kinase inhibitors

Receptos patents new GLP-1 receptor modulators

New pegylated nitroimidazole conjugates divulged by researchers in the U.S. and Taiwan

Novel DGAT1 inhibitors synthesized at Daiichi Sankyo

University of Tokushima discloses novel anticancer compounds

New MISRII antibodies presented by The Fox Chase Cancer Center

Swiss and U.S. scientists patent new agents for malaria and toxoplasmosis

Updated results presented from the GAUSS trial of AMG-145

Microbiotix enters licensing agreement for MBX-700 and MBX-701

TheraVida reports topline Tolenix data in overactive bladder and urinary incontinence

NGM signs agreement with Janssen for novel therapeutics for diabetes

Zogenix reports data from phase I Relday trial

FDA approves next-generation Xience Xpedition drug eluting stent system

PharmaEngine and BeBetter enter oncology collaboration

EPIRUS' BOW-015 shows bioequivalence to Remicade in phase I study

Phase I trial of mibefradil for cancer completed

Repligen and Pfizer sign worldwide licensing agreement for spinal muscular atrophy

Biogen's phase III trial of dexpramipexole in ALS fails to meet endpoints

Second phase IIa study of Z-160 begins for chronic neuropathic pain

Celtaxsys commences first-in-human study of treatment for pulmonary inflammation

Alnylam files application for phase I study of RNAi therapeutic in the U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.